SORT BY

FILTER BY

fastest growing stats

also on other fortune lists

100 Fastest-Growing Companies

Courtesy of Gilead Sciences

63

Gilead Sciences

GILD

Hepatitis C treatments are an integral part of the biotech’s product line. Recent approval for a competitor’s comprehensive Hep C drug adds new pressure.

Looking for leads, investment insights, or competitive intelligence?

Location

Foster City, Calif.

Industry

Pharmaceuticals

Sector

Health Care

Current Streak

3

Years on List

8

CEO

John Milligan

Revenue and net income for the four quarters ended on or before April 30, 2017. Total return for the period ended June 30, 2017.
Gilead Sciences is also featured in these fortune lists
Revenue, Net Income
$ millions
Revenue past four quarters ($M)$29,101
Net Income past four quarters ($M)$12,637
Growth Rates and Ranks
Revenue 3 Yr Growth Rank48
Revenue 3 Yr Annual Growth Rate32%
EPS 3 Yr Growth Rank30
EPS 3 Yr Annual Growth Rate58%
Total Return 3 Yr Rank96
Total Return 3 Yr Annual Rate-4%
Beat S&P 500 (9.6%)No
P/E Ratio9
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Gilead Sciences

Gilead's New Cancer Gene Therapy Has Been Approved by the FDA

The price of the drug, which is to be administered just once to each patient, will be $373,000.

Read More →
The Trump White House Gave These Mutual Funds a Big Boost

They're more popular than ever, even though the political winds are against them.

Read More →
The Way We Treat Cancer Will Be Revolutionized As Gene Therapy Comes to the U.S.

FDA approves Novartis treatment that reengineers human cells to kill cancer

Read More →